ATE167680T1 - Pteridin-nukleotidderivate als fluoreszierende sonden - Google Patents

Pteridin-nukleotidderivate als fluoreszierende sonden

Info

Publication number: ATE167680T1
Authority: AT; Austria
Prior art keywords: pteridine; fluorescent probe; fluorescent; nucleotide derivatives; pteridine nucleotide
Prior art date: 1994-05-18

Application number

AT95917197T

Other languages

English (en)

Inventor

Mary E Hawkins

Wolfgang Pfleiderer

Michael Dean Davis

Frank Balis

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-18

Filing date

1995-04-25

Publication date

1998-07-15

1995-04-25 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

1998-07-15 Application granted granted Critical

1998-07-15 Publication of ATE167680T1 publication Critical patent/ATE167680T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/22—Pteridine radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT95917197T 1994-05-18 1995-04-25 Pteridin-nukleotidderivate als fluoreszierende sonden ATE167680T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/245,923 US5525711A (en)	1994-05-18	1994-05-18	Pteridine nucleotide analogs as fluorescent DNA probes

Publications (1)

Publication Number	Publication Date
ATE167680T1 true ATE167680T1 (de)	1998-07-15

Family

ID=22928654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95917197T ATE167680T1 (de)	1994-05-18	1995-04-25	Pteridin-nukleotidderivate als fluoreszierende sonden

Country Status (10)

Country	Link
US (2)	US5525711A (de)
EP (1)	EP0759927B1 (de)
JP (2)	JPH10500949A (de)
AT (1)	ATE167680T1 (de)
AU (1)	AU688036B2 (de)
CA (1)	CA2190588C (de)
DE (1)	DE69503129T2 (de)
DK (1)	DK0759927T3 (de)
ES (1)	ES2118593T3 (de)
WO (1)	WO1995031469A1 (de)

Families Citing this family (945)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
AU679566B2 (en)	1993-09-03	1997-07-03	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US6787304B1 (en)	1994-12-28	2004-09-07	Georgetown University	Fluorometric assay for detecting nucleic acid cleavage
US20030165908A1 (en) *	1994-12-30	2003-09-04	Georgetown University	Fluorometric assay for detecting nucleic acid cleavage
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US6379911B2 (en) *	1996-02-23	2002-04-30	Albert Einstein College Of Medicine Of Yeshiva University	Enzyme detection/assay method and substrates
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US6451530B1 (en)	1996-12-13	2002-09-17	The United States Of America As Represented By The Department Of Health And Human Services	Fluorescent nucleotide analog hairpin formation for detection of nucleic acid hybridization
US6020162A (en) *	1997-06-13	2000-02-01	The Rockefeller University	Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
US5872011A (en) *	1997-06-13	1999-02-16	The Rockefeller University	Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
AU707186B2 (en)	1997-07-01	1999-07-01	Transgene S.A.	Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
JP2002510319A (ja)	1997-07-01	2002-04-02	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
AU753270B2 (en)	1998-05-21	2002-10-10	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
EP1080103A4 (de)	1998-05-21	2003-07-02	Isis Pharmaceuticals Inc	Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
DE19858588B4 (de) *	1998-08-22	2016-04-07	Qiagen Gmbh	Farbstoffmarkiertes Oligonukleotid zum Markieren eines Nukleinsäuremoleküls
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
WO2000014101A1 (en) *	1998-09-08	2000-03-16	The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs
US6716971B1 (en)	1998-09-08	2004-04-06	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
JP2002536320A (ja) *	1999-02-02	2002-10-29	カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント	プテリジン誘導体の免疫抑制作用
US6946465B2 (en)	1999-02-02	2005-09-20	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
EP2177627B1 (de)	1999-02-23	2012-05-02	Caliper Life Sciences, Inc.	Manipulation von Mikropartikeln in mikrofluidischen Systemen
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
DE69926053T2 (de)	1999-04-27	2006-04-27	Transgene S.A.	Verfahren zur Herstellung von Säugetier-Zellinien
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
WO2001036668A1 (de) *	1999-11-16	2001-05-25	Atto-Tec Gmbh	Farbstoffmarkiertes oligonukleotid zum markieren eines nukleinsäuremoleküls
WO2001038585A2 (en) *	1999-11-24	2001-05-31	The Regents Of The University Of California	Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression
WO2001047563A1 (en)	1999-12-28	2001-07-05	Transgene S.A.	Use of lithium (li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
US20040146918A1 (en) *	2000-02-18	2004-07-29	Weiner Michael L.	Hybrid nucleic acid assembly
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
GB0023057D0 (en)	2000-09-20	2000-11-01	Randox Lab Ltd	Liquid reagent
CA2425779C (en)	2000-10-12	2013-08-06	University Of Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
JP2004533815A (ja)	2001-03-14	2004-11-11	ミリアド・ジェネティックス・インコーポレイテッド	Ｔｓｇ１０１−ｇａｇ相互作用およびその使用
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
KR100628425B1 (ko)	2001-06-20	2006-09-28	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP2270024B1 (de)	2001-06-21	2018-10-24	Ionis Pharmaceuticals, Inc.	Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
BR0211900A (pt) *	2001-08-14	2004-08-24	Toyama Chemical Co Ltd	Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
JP2005536439A (ja)	2001-09-18	2005-12-02	ジェネンテック・インコーポレーテッド	腫瘍の診断及び治療のための組成物と方法
ATE509120T1 (de)	2001-09-18	2011-05-15	Carnegie Inst Of Washington	Fusionsproteine zur detektion von analyten
NZ566396A (en)	2001-10-09	2009-07-31	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
CA2481507A1 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20040092470A1 (en) *	2002-06-18	2004-05-13	Leonard Sherry A.	Dry powder oligonucleotide formualtion, preparation and its uses
WO2004013160A2 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
CA2499770A1 (en)	2002-09-20	2004-04-01	Yale University	Riboswitches, methods for their use, and compositions for use with riboswitches.
EP1549767A4 (de)	2002-09-26	2006-06-07	Amgen Inc	Modulation der expression von forkhead-box o1a
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2957568B1 (de)	2002-11-05	2016-12-21	Ionis Pharmaceuticals, Inc.	Zusammensetzungen mit alternierenden 2'-modifizierten nukleosiden zur verwendung bei der genmodulation
EP1560839A4 (de)	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Chimäre oligomere verbindungen und derenverwendung in der genmodulation
WO2004044181A2 (en)	2002-11-13	2004-05-27	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein b expression
DK2336318T3 (da)	2002-11-13	2013-07-15	Genzyme Corp	Antisense-modulering af apolipoprotein b-ekspression
DK1569685T3 (da)	2002-11-15	2012-11-12	Univ Colorado Regents	Komplementmodulatorer rettet mod komplementreceptor-2
WO2004046330A2 (en) *	2002-11-15	2004-06-03	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP2410332A1 (de)	2002-11-21	2012-01-25	The University Of Utah	Methode zur Identifizierung von purinergen Modulatoren des Geruchssystems
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
JP4886298B2 (ja)	2002-12-20	2012-02-29	キアゲンゲゼルシャフトミットベシュレンクテルハフツング	核酸増幅
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
US7781163B2 (en)	2003-01-08	2010-08-24	Lesley Davenport	G-quadruplex binding assays and compounds therefor
EP1597366B1 (de)	2003-02-11	2012-11-21	Antisense Therapeutics Ltd	Modulation der expression des insulinähnlichen wachstumsfaktor i-rezeptors
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040175704A1 (en)	2003-03-06	2004-09-09	Stratagene	Compositions and methods for polynucleotide sequence detection
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US7276599B2 (en)	2003-06-02	2007-10-02	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
WO2005002507A2 (en)	2003-06-03	2005-01-13	Isis Pharmaceuticals, Inc.	Modulation of survivin expression
US7786290B2 (en)	2003-06-13	2010-08-31	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
ES2356154T3 (es)	2003-07-21	2011-04-05	Transgene S.A.	Citoquinas multifuncionales.
EP1648914A4 (de)	2003-07-31	2009-12-16	Regulus Therapeutics Inc	Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
EP1508624A1 (de) *	2003-08-22	2005-02-23	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methode zur Quantifizierung von integrierten Viren
SI1660057T1 (sl)	2003-08-27	2012-10-30	Ophthotech Corp	Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
JP5379347B2 (ja) *	2003-09-18	2013-12-25	アイシスファーマシューティカルズ，インコーポレーテッド	４’−チオヌクレオシドおよびオリゴマー化合物
PE20050469A1 (es)	2003-09-18	2005-09-10	Lilly Co Eli	Modulacion de la expresion de eif4e
PL1678194T3 (pl)	2003-10-10	2014-01-31	Alchemia Oncology Pty Ltd	Modulowanie syntezy i degradacji hialuronianu w leczeniu choroby
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
ATE453405T1 (de)	2003-11-17	2010-01-15	Genentech Inc	Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
EP1711606A2 (de)	2004-01-20	2006-10-18	Isis Pharmaceuticals, Inc.	Modulation der expression des glucocorticoidrezeptors
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (de)	2004-03-15	2015-01-28	Isis Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
CA2561741C (en)	2004-04-05	2016-09-27	Alnylam Pharmaceuticals, Inc.	Processes and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
AU2005323437B2 (en)	2004-04-30	2011-10-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a C5-modified pyrimidine
WO2005107404A2 (en) *	2004-05-03	2005-11-17	The Penn State Research Foundation	Methods and systems for nanoparticle enhancement of signals
EP3225633B1 (de)	2004-05-21	2020-03-25	The UAB Research Foundation	Variable lymphozytenrezeptoren, verwandte polypeptide und nukleinsäuren sowie verwendung dafür
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
CA2569419A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US20080286880A1 (en) *	2004-07-07	2008-11-20	The Penn State Research Foundation	Methods and Systems for Nanoparticle Enhancement of Signals
US7427675B2 (en)	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
EP2314308A1 (de)	2004-09-21	2011-04-27	BioNTech AG	Verwendung von Mikroproteinen als Tryptase Inhibitoren
WO2006032143A1 (en)	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
US7851152B2 (en) *	2004-09-25	2010-12-14	Yaodong Chen	Fluorescent base analogues' usage in the characterization of nucleic acid molecules and their interactions
JP5111113B2 (ja)	2004-12-13	2012-12-26	サネシスファーマシューティカルズ，インコーポレイテッド	Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
DE602006014362D1 (de)	2005-02-02	2010-07-01	Univ Bayreuth	Esterasen zur überwachung der proteinbiosynthese in vitro
CN101175769A (zh)	2005-03-10	2008-05-07	健泰科生物技术公司	用于调控血管完整性的方法和组合物
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
JP5329949B2 (ja)	2005-05-31	2013-10-30	エコーレポリテクニークフェデラーレデローザンヌ	遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
DE602006017405D1 (de)	2005-08-11	2010-11-18	Synthetic Genomics Inc	Verfahren zur in vitro-rekombination
KR20080036646A (ko)	2005-08-17	2008-04-28	메덱시스 에스.에이.	Ｃｋ１９ 발현 측정을 위한 조성물 및 방법
DE602006019455D1 (de)	2005-08-29	2011-02-17	Regulus Therapeutics Inc	Verfahren für mir-122a-modulation
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
EP2096170B1 (de)	2005-09-19	2011-08-10	Isis Pharmaceuticals, Inc.	Modulation der Glucagonrezeptorexpression
WO2007035759A1 (en)	2005-09-19	2007-03-29	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	Modulation of glucocorticoid receptor expression
CA2625891A1 (en)	2005-10-14	2007-04-26	Carlton D. Donald	Inhibition of pax2 by defb1 induction as a therapy for cancer
US8080534B2 (en) *	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2325315B1 (de)	2005-10-28	2014-05-07	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
EP2363134B1 (de)	2005-11-09	2014-01-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression von Faktor V Leiden Mutationsgen
EP1966377A2 (de)	2005-11-21	2008-09-10	Isis Pharmaceuticals, Inc.	Modulation der eif4e-bp2-expression
US8313901B2 (en) *	2005-12-21	2012-11-20	Yale University	Methods and compositions related to the modulation of riboswitches
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
JP5213723B2 (ja)	2006-01-27	2013-06-19	アイシスファーマシューティカルズ，インコーポレーテッド	マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
EP1984381B1 (de)	2006-01-27	2010-09-29	Isis Pharmaceuticals, Inc.	6-modifizierte bicyclische nukleinsäureanaloga
KR101362681B1 (ko)	2006-03-31	2014-02-13	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법
WO2007125173A2 (en) *	2006-05-03	2007-11-08	Baltic Technology Development, Ltd.	Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
WO2007131237A2 (en) *	2006-05-05	2007-11-15	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of ptp1b
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
ES2389737T3 (es)	2006-05-11	2012-10-31	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos modificados en 5'
BRPI0712034A2 (pt)	2006-05-19	2012-01-10	Alnylam Pharmaceuticals Inc	modulação de rnai de aha e usos terapêuticos do mesmo
WO2007137220A2 (en)	2006-05-22	2007-11-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
EP2023938A4 (de) *	2006-05-23	2010-11-10	Isis Pharmaceuticals Inc	Modulation von chrebp-expression
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
WO2008009079A2 (en)	2006-07-20	2008-01-24	Gilead Sciences, Inc.	Substituted pteridines useful for the treatment and prevention of viral infections
US9259426B2 (en)	2006-07-20	2016-02-16	Gilead Sciences, Inc.	4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008033866A2 (en) *	2006-09-11	2008-03-20	Yale University	Methods and compositions for the use of lysine riboswitches
WO2008036929A2 (en) *	2006-09-21	2008-03-27	Alnylam Pharmaceuticals, Inc.	Complex for transferring an anionic substance into a cell
WO2008042156A1 (en) *	2006-09-28	2008-04-10	Northwestern University	Maximizing oligonucleotide loading on gold nanoparticle
EP2069788B1 (de)	2006-10-05	2017-03-01	Massachusetts Institute of Technology	Multifunktionelle kodierte partikel für hochdurchsatzanalysen
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
JP2010512327A (ja)	2006-12-11	2010-04-22	ユニヴァーシティーオブユタリサーチファウンデーション	病的血管形成および脈管透過性の処置用の組成物および方法
EP2913341A1 (de)	2006-12-22	2015-09-02	University of Utah Research Foundation	Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
CA2675355C (en)	2007-01-30	2015-04-28	Transgene S.A.	Papillomavirus vaccine
CA2691066C (en)	2007-02-09	2018-07-31	Northwestern University	Particles for detecting intracellular targets
KR20100015757A (ko)	2007-03-22	2010-02-12	예일 유니버시티	택일적 스플라이싱을 조절하는 리보스위치와 관련된 방법 및 조성물
CA2682161A1 (en)	2007-03-29	2008-10-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from ebola virus
JP2010528616A (ja) *	2007-05-29	2010-08-26	イェールユニバーシティー	オルタナティブスプライシングとｒｎａのスプライシングを調節するリボスイッチに関連する方法と組成物
CN101849020A (zh) *	2007-05-29	2010-09-29	耶鲁大学	核糖开关及使用核糖开关的方法和组合物
MX2009013046A (es)	2007-05-30	2010-02-17	Univ Northwestern	Nanoparticulas con grupo funcional de acido nucleico para aplicaciones terapeuticas.
US8278425B2 (en)	2007-05-30	2012-10-02	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en) *	2007-07-05	2012-10-02	Isis Pharmaceuticals, Inc.	6-disubstituted or unsaturated bicyclic nucleic acid analogs
CN101821277B (zh)	2007-08-15	2014-05-07	Isis制药公司	四氢吡喃核酸类似物
ES2391358T3 (es)	2007-08-24	2012-11-23	Julius-Maximilians-Universitat Wurzburg	Péptidos receptores ciclados dobles mutantes que inhiben anticuerpos de Beta 1-adrenoceptor
WO2009032693A2 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2697957A1 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) *	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
WO2009060124A2 (en) *	2007-11-05	2009-05-14	Baltic Technology Development, Ltd.	Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8916531B2 (en)	2007-11-20	2014-12-23	Isis Pharmaceuticals, Inc.	Modulation of CD40 expression
EP2848688A1 (de)	2007-12-10	2015-03-18	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
CA2709875C (en)	2008-01-02	2019-07-16	Tekmira Pharmaceuticals Corporation	Improved compositions and methods for the delivery of nucleic acids
EP2265627A2 (de) *	2008-02-07	2010-12-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexitolnukleinsäureanaloga
JP2011518117A (ja)	2008-03-05	2011-06-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
EP2274423A2 (de) *	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
DK2281042T3 (en)	2008-04-18	2015-11-09	Baxter Int	Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes
CA2722668A1 (en) *	2008-04-29	2009-11-05	Wyeth Llc	Methods for treating inflammation
MX2011002143A (es)	2008-08-25	2011-07-20	Excaliard Pharmaceuticals Inc	Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
US8318693B2 (en)	2008-09-02	2012-11-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mutant EGFR gene
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
EP2361256B1 (de)	2008-09-24	2013-04-10	Isis Pharmaceuticals, Inc.	Cyclohexenylverbindungen als nukleinsäureanaloga
JP5529142B2 (ja)	2008-09-25	2014-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	血清アミロイドａ遺伝子の発現を阻害するための脂質製剤組成物および方法
PL2350043T3 (pl)	2008-10-09	2014-09-30	Tekmira Pharmaceuticals Corp	Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
KR101773551B1 (ko)	2008-10-15	2017-08-31	아이오니스 파마수티컬즈, 인코포레이티드	인자 １１ 발현의 조정
WO2010048228A2 (en)	2008-10-20	2010-04-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin
CN102264374B (zh)	2008-10-24	2015-01-07	Isis制药公司	5′和2′双取代的核苷和由其制备的低聚化合物
US8987435B2 (en)	2008-10-24	2015-03-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
EP2365803B1 (de)	2008-11-24	2017-11-01	Northwestern University	Polyvalente rna-nanoteilchen-zusammensetzungen
KR101881596B1 (ko)	2008-12-02	2018-07-24	웨이브 라이프 사이언시스 재팬 인코포레이티드	인 원자 변형된 핵산의 합성 방법
ES2629630T3 (es)	2008-12-04	2017-08-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
CN102307997B (zh)	2008-12-04	2018-03-30	库尔纳公司	通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
KR101840618B1 (ko)	2008-12-04	2018-03-20	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
NZ593618A (en)	2008-12-10	2013-02-22	Alnylam Pharmaceuticals Inc	Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2382235B1 (de)	2008-12-19	2016-02-24	Christiane Hilger	Neues caviidae-allergen und anwendungen davon
EP2367564A1 (de)	2008-12-22	2011-09-28	Universität Regensburg	Norrin bei der behandlung von erkrankungen im zusammenhang mit erhöhter tgf-beta-aktivität
US20100184844A1 (en) *	2009-01-08	2010-07-22	Northwestern University	Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
JP2012516155A (ja)	2009-01-27	2012-07-19	キアゲンゲーザーズバーグ	エンドポイント均一蛍光検出を用いた好熱性ヘリカーゼ依存性増幅技術
WO2010088537A2 (en)	2009-01-29	2010-08-05	Alnylam Pharmaceuticals, Inc.	Improved lipid formulation
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
WO2010091308A2 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
ES2560107T3 (es)	2009-02-12	2016-02-17	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
CN102439149B (zh)	2009-02-12	2018-01-02	库尔纳公司	通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
CN102369211B (zh)	2009-02-13	2015-04-29	诺华股份有限公司	编码非核糖体肽合酶的生物合成簇的核酸分子及其用途
US20120041051A1 (en)	2009-02-26	2012-02-16	Kevin Fitzgerald	Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
WO2010102058A2 (en)	2009-03-04	2010-09-10	Curna, Inc.	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
JP6032724B2 (ja)	2009-03-12	2016-11-30	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
CN102482677B (zh)	2009-03-16	2017-10-17	库尔纳公司	通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
CA2755404C (en)	2009-03-17	2020-03-24	Joseph Collard	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CN102449170A (zh)	2009-04-15	2012-05-09	西北大学	寡核苷酸功能化的纳米颗粒的递送
EP3524275A1 (de)	2009-04-22	2019-08-14	Massachusetts Institute Of Technology	Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
DE102010018878B4 (de)	2009-04-30	2013-09-26	Julius-Maximilians-Universität Würzburg	Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor
EP2424987B1 (de)	2009-05-01	2017-11-15	CuRNA, Inc.	Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
WO2010129687A1 (en)	2009-05-05	2010-11-11	Alnylam Pharmaceuticals, Inc	Methods of delivering oligonucleotides to immune cells
NZ711583A (en)	2009-05-05	2017-03-31	Arbutus Biopharma Corp	Lipid compositions
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
EP2427553A4 (de)	2009-05-06	2012-11-07	Opko Curna Llc	Behandlung von lipidtransport- und stoffwechselgenbedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein lipidtransport- und stoffwechselgen
US20120107331A1 (en)	2009-05-15	2012-05-03	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
US8957037B2 (en)	2009-05-18	2015-02-17	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh)	2009-05-22	2017-09-26	库尔纳公司	通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en)	2009-05-28	2010-12-02	Joseph Collard	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR102066189B1 (ko)	2009-06-10	2020-01-14	알닐람 파마슈티칼스 인코포레이티드	향상된 지질 조성물
JP6128846B2 (ja)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
CN102695797B (zh)	2009-06-16	2018-05-25	库尔纳公司	通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
WO2010151671A2 (en)	2009-06-24	2010-12-29	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
ES2583691T3 (es)	2009-06-26	2016-09-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
EP2462229B1 (de)	2009-08-05	2016-05-11	CuRNA, Inc.	Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
MX2012001592A (es)	2009-08-07	2012-05-22	Transgene Sa	Composicion para el tratamiento de la infección del virus de la hepatitis b.
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
BR112012007877A2 (pt)	2009-08-26	2019-09-24	Medizinische Hochschule Hannover	meios e métodos para produção de polissacarídeos capsulares artificiais de neisseria meningitidis
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
CA2778442A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US20110129832A1 (en)	2009-10-27	2011-06-02	Swift Biosciences, Inc.	Polynucleotide Primers and Probes
EP2494075B1 (de)	2009-10-30	2018-04-04	Northwestern University	Templatgesteuerte nanokonjugate
AU2010315867A1 (en)	2009-11-03	2012-06-21	University Of Virginia Patent Foundation	Versatile, visible method for detecting polymeric analytes
CA2781469A1 (en)	2009-11-23	2011-05-26	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
RU2015132142A (ru)	2009-11-30	2015-12-20	Дженентек, Инк.	Композиции и способы для диагностики и лечения опухоли
NO2513310T3 (de)	2009-12-16	2018-03-31
NO2516648T3 (de)	2009-12-23	2018-04-07
CA2782375C (en)	2009-12-23	2023-10-31	Opko Curna, Llc	Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
KR101853508B1 (ko)	2009-12-29	2018-06-20	큐알엔에이, 인크.	종양 단백질 63 (ｐ63)에 대한 천연 안티센스 전사체의 억제에 의한 ｐ63에 관련된 질환의 치료
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
CN102906264B (zh)	2010-01-04	2017-08-04	库尔纳公司	通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
JP5963680B2 (ja)	2010-01-06	2016-08-03	カッパーアールエヌエー，インコーポレイテッド	膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2786535C (en)	2010-01-11	2019-03-26	Curna, Inc.	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
EP2524042A2 (de)	2010-01-12	2012-11-21	Yale University	Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
JP5981850B2 (ja)	2010-01-25	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
WO2011097407A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
KR20130004579A (ko)	2010-02-23	2013-01-11	제넨테크, 인크.	종양의 진단 및 치료를 위한 조성물 및 방법
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP2544703A4 (de)	2010-03-12	2013-09-18	Brigham & Womens Hospital	Verfahren zur behandlung von gefässentzündungserkrankungen
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
WO2011115817A1 (en)	2010-03-16	2011-09-22	Isis Pharmaceuticals, Inc.	Methods of preparing 2'-o-substituted purine nucleosides
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US8889350B2 (en)	2010-03-26	2014-11-18	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
JP5860029B2 (ja)	2010-03-29	2016-02-16	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	トランスチレチン（ＴＴＲ）関連眼アミロイドーシスのためのｓｉＲＮＡ療法
JP2013523162A (ja)	2010-04-06	2013-06-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
CN102858979B (zh)	2010-04-09	2018-01-26	库尔纳公司	通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
US20110269194A1 (en)	2010-04-20	2011-11-03	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
JP6005628B2 (ja)	2010-04-28	2016-10-12	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
JP5896175B2 (ja)	2010-04-29	2016-03-30	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	トランスサイレチン発現の調節
MA34291B1 (fr)	2010-05-03	2013-06-01	Genentech Inc	Compositions et méthodes de diagnostic et de traitement d'une tumeur
KR101936011B1 (ko)	2010-05-03	2019-01-07	큐알엔에이, 인크.	시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
WO2011138457A1 (en)	2010-05-07	2011-11-10	Technische Universität Graz	Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2800018C (en)	2010-05-21	2021-09-28	Universitaet Fuer Bodenkultur Wien	Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
US8895528B2 (en)	2010-05-26	2014-11-25	Curna, Inc.	Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US8628914B2 (en)	2010-05-26	2014-01-14	Qiagen Gaithersburg, Inc.	Quantitative helicase assay
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
AU2011261434B2 (en)	2010-06-02	2015-11-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
EP2576617B1 (de)	2010-06-04	2016-04-27	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin	MONOKLONALE ANTIKÖRPER, DIE AUF Aß-OLIGOMERE ZIELEN
CA2802059C (en)	2010-06-07	2020-05-12	Firefly Bioworks, Inc.	Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en)	2010-06-08	2014-09-30	Isis Pharmaceuticals, Inc.	Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
EP2582397A4 (de)	2010-06-15	2014-10-29	Isis Pharmaceuticals Inc	Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
CN103038253A (zh)	2010-06-18	2013-04-10	西伯尔科学有限公司	作为用来稳定生物屏障的活性剂的肽
WO2011163466A1 (en)	2010-06-23	2011-12-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (nrg-1)
JP5998131B2 (ja)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
AU2011282217B2 (en)	2010-07-19	2015-12-03	Ionis Pharmaceuticals, Inc.	Modulation of dystrophia myotonica-protein kinase (DMPK) expression
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
MX2013001836A (es)	2010-08-26	2013-07-29	Hoffmann La Roche	Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
KR101886457B1 (ko)	2010-10-06	2018-08-07	큐알엔에이, 인크.	시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
EP2625292B1 (de)	2010-10-07	2018-12-05	The General Hospital Corporation	Krebsbiomarker
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
WO2012054723A2 (en)	2010-10-22	2012-04-26	Opko Curna Llc	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
DK2633052T3 (en)	2010-10-27	2018-07-16	Curna Inc	TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
US9339513B2 (en)	2010-11-09	2016-05-17	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2638163B1 (de)	2010-11-12	2017-05-17	The General Hospital Corporation	Polycomb-assoziierte nicht-kodierende rnas
EP3521451A1 (de)	2010-11-17	2019-08-07	Ionis Pharmaceuticals, Inc.	Modulation von alpha-synuklein-expression
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012079046A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2012078967A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (epo) production
WO2012095841A1 (en)	2011-01-10	2012-07-19	State Of Israel, Ministry Of Agriculture And Rural Development, A.R.O. - Volcani Center	Improved tomato plants
WO2012097261A2 (en)	2011-01-14	2012-07-19	The General Hospital Corporation	Methods targeting mir-128 for regulating cholesterol/lipid metabolism
CN103391777A (zh)	2011-02-02	2013-11-13	普林斯顿大学理事会	作为病毒产生调节剂的去乙酰化酶调节剂
PT2670411T (pt)	2011-02-02	2019-06-18	Excaliard Pharmaceuticals Inc	Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
WO2012109157A2 (en)	2011-02-07	2012-08-16	The Governing Council Of The University Of Toronto	Bioprobes and methods of use thereof
WO2012109395A1 (en)	2011-02-08	2012-08-16	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012113779A1 (en)	2011-02-21	2012-08-30	Medizinische Universität Wien	Means and methods for treating a disease or disorder related to lymphangiogenesis or preventing metastasis
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
CA3217805A1 (en)	2011-03-29	2012-10-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of tmprss6 gene
US10086043B2 (en)	2011-04-03	2018-10-02	The General Hospital Corporation	Efficient protein expression in vivo using modified RNA (MOD-RNA)
US20140186844A1 (en)	2011-04-26	2014-07-03	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
EP2523002A1 (de)	2011-05-13	2012-11-14	Universität Bayreuth	Verwendung von magnetischen Nanoteilchen als intrazelluläre Liftsysteme
EP2522689A1 (de)	2011-05-13	2012-11-14	Universität Bayreuth	Nicht virale Transfektionssysteme
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
TWI678375B (zh)	2011-06-09	2019-12-01	可娜公司	藉由抑制共濟蛋白（ｆｒａｔａｘｉｎ，ｆｘｎ）之天然反股轉錄本治療ｆｘｎ相關疾病
RU2631805C2 (ru)	2011-06-21	2017-09-26	Элнилэм Фармасьютикалз, Инк.	Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
EP2723351B1 (de)	2011-06-21	2018-02-14	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
KR102232287B1 (ko)	2011-06-21	2021-03-29	알닐람 파마슈티칼스 인코포레이티드	안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
EP4134433A1 (de)	2011-06-23	2023-02-15	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
US9222093B2 (en)	2011-06-30	2015-12-29	The University Of Hong Kong	Two-way, portable riboswitch mediated gene expression control device
BR112014001244A2 (pt)	2011-07-19	2017-02-21	Wave Life Sciences Pte Ltd	métodos para a síntese de ácidos nucléicos funcionalizados
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
WO2013017656A1 (en)	2011-08-02	2013-02-07	Medizinische Universität Wien	Antagonists of ribonucleases for treating obesity
EP3205725B1 (de)	2011-08-11	2019-03-27	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und verwendungen davon
WO2013024175A2 (en)	2011-08-17	2013-02-21	Technische Universität München	Diagnostic means and methods for type 2 diabetes
EP2751270B1 (de)	2011-08-29	2018-08-22	Ionis Pharmaceuticals, Inc.	Oligomer-konjugat-komplexe und ihre verwendung
US9976138B2 (en)	2011-08-29	2018-05-22	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
EP2756080B1 (de)	2011-09-14	2019-02-20	Translate Bio MA, Inc.	Multimere oligonukleotidverbindungen
CN104023749B (zh)	2011-09-14	2019-12-17	西北大学	能穿过血脑屏障的纳米缀合物
WO2013040548A2 (en)	2011-09-17	2013-03-21	Yale University	Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
CN104011210B (zh)	2011-10-11	2018-05-01	布里格姆及妇女医院股份有限公司	神经退行性病症中的microRNA
LT2766393T (lt)	2011-10-14	2018-10-10	F. Hoffmann-La Roche Ag	Antikūnai prieš htra1 ir jų naudojimo būdai
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
CA2895077A1 (en)	2011-12-12	2013-06-20	Beverly Packard	In vivo delivery of oligonucleotides
RU2014129918A (ru)	2011-12-22	2016-02-10	Медицинише Универзитет Виен	Циклотиды в качестве иммунодепрессантов
IL321422A (en)	2012-01-11	2025-08-01	Ionis Pharmaceuticals Inc	Compositions and methods for modulation of ikbkap splicing
EP2626066A1 (de)	2012-02-10	2013-08-14	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Kombinationstherapie mit selektiven VEGFR-2-Inhibitoren und MEK-Inhibitoren
AU2013225084B2 (en)	2012-02-29	2017-07-20	Syngenta Participations Ag	Modulation of seed vigor
JP6509723B2 (ja)	2012-03-13	2019-05-08	スウィフトバイオサイエンシーズ，インコーポレイテッド	核酸ポリメラーゼによる基質ポリヌクレオチドの大きさ制御されたホモポリマーテーリングのための方法および組成物
EP2825648B1 (de)	2012-03-15	2018-09-05	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
CA2907072A1 (en)	2012-03-16	2013-09-19	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of dmpk
AU2013202595B2 (en)	2012-03-30	2016-04-21	Biogen Ma Inc.	Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CA2871073A1 (en)	2012-04-20	2013-10-24	Aptamir Therapeutics, Inc.	Mirna modulators of thermogenesis
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP2841572B1 (de)	2012-04-27	2019-06-19	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
CN104583398A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节基因表达的组合物和方法
WO2013173638A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating smn gene family expression
US20160002624A1 (en)	2012-05-17	2016-01-07	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
US9487780B2 (en)	2012-06-01	2016-11-08	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013181665A1 (en)	2012-06-01	2013-12-05	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20130330389A1 (en)	2012-06-08	2013-12-12	The Regents Of The University Of Michigan	Ultrasound-triggerable agents for tissue engineering
CA2877441A1 (en)	2012-07-02	2014-01-09	Medizinische Universitat Wien	Complement split product c4d for the treatment of inflammatory conditions
EP2870239B1 (de)	2012-07-04	2018-10-31	Wintershall Holding GmbH	Verfahren zur mikrobiologischen herstellung von beta glucan; dafür geeignete, genetisch modifizierte mikroorganismen
ES2862073T3 (es)	2012-07-13	2021-10-06	Wave Life Sciences Ltd	Grupo auxiliar asimétrico
CN112007045A (zh)	2012-07-13	2020-12-01	波涛生命科学有限公司	手性控制
BR112015000723A2 (pt)	2012-07-13	2017-06-27	Shin Nippon Biomedical Laboratories Ltd	adjuvante de ácido nucléico quiral
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
US20150216892A1 (en)	2012-08-03	2015-08-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
EP2695950A1 (de)	2012-08-10	2014-02-12	Blackfield AG	Marker für die Empfindlichkeit auf einen Hemmer des Fibroblastenwachstumsrezeptors
WO2014028739A1 (en)	2012-08-15	2014-02-20	Isis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
DK3421602T3 (da)	2012-09-06	2021-05-10	Univ Chicago	Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
EP2708241A1 (de)	2012-09-12	2014-03-19	Netris Pharma	Rekombinantes Fc-Fusionsprotein der zwei Immunoglobulin-Domänen von UNC5
EP2708231A1 (de)	2012-09-12	2014-03-19	Netris Pharma	Kombinierte Behandlung mit Netrin-1-Störwirkstoff und chemotherapeutischem Wirkstoff
US9695418B2 (en)	2012-10-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
EP2906255B1 (de)	2012-10-12	2023-02-22	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
US20150275208A1 (en)	2012-10-12	2015-10-01	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2014066443A1 (en)	2012-10-23	2014-05-01	Emory University	Gm-csf and il-4 conjugates, compositions, and methods related thereto
CA2887702C (en)	2012-10-26	2023-08-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
WO2014071358A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
AU2013337264B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
US8883857B2 (en)	2012-12-07	2014-11-11	Baylor College Of Medicine	Small molecule xanthine oxidase inhibitors and methods of use
WO2014093537A1 (en)	2012-12-11	2014-06-19	Isis Pharmaceuticals, Inc.	Competitive modulation of micrornas
EP3939614A1 (de)	2013-01-18	2022-01-19	Foundation Medicine, Inc.	Verfahren zur behandlung cholangiokarzinom
EP3778618A1 (de)	2013-02-04	2021-02-17	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und verwendungen davon
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
KR20150130430A (ko)	2013-03-14	2015-11-23	아이시스 파마수티컬즈 인코포레이티드	타우 발현을 조절하는 조성물 및 방법
KR102605775B1 (ko)	2013-03-14	2023-11-29	알닐람 파마슈티칼스 인코포레이티드	보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
CN105283466A (zh)	2013-03-14	2016-01-27	安第斯生物技术股份有限公司	用于检测和治疗多发性骨髓瘤的方法
WO2014153209A1 (en)	2013-03-14	2014-09-25	Andes Biotechnologies S.A.	Antisense oligonucletotides for treatment of cancer stem cells
US9347095B2 (en)	2013-03-15	2016-05-24	Bio-Rad Laboratories, Inc.	Digital assays for mutation detection
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
EP2978446B1 (de)	2013-03-27	2020-03-04	The General Hospital Corporation	Anti-cd33 antikörper zur behandlung von morbus alzheimer
JP2016522679A (ja)	2013-04-04	2016-08-04	プレジデントアンドフェローズオブハーバードカレッジ	ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
WO2015012916A2 (en)	2013-04-23	2015-01-29	Northwestern University	Metal-ligand coordination polymer nanoparticles and methods for making
BR112015027322A8 (pt)	2013-05-01	2018-01-02	Isis Pharmaceuticals Inc	Compostos antissenso conjugados e sua utilização
MX379208B (es)	2013-05-22	2025-03-10	Alnylam Pharmaceuticals Inc	Composiciones de arni de serpina1 y sus metodos de uso.
EP3828276A1 (de)	2013-05-22	2021-06-02	Alnylam Pharmaceuticals, Inc.	Tmprss6-irna-zusammensetzungen und verfahren zur verwendung davon
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
AU2014280847B2 (en)	2013-06-13	2019-07-04	Antisense Therapeutics Ltd	Combination therapy
US20160122761A1 (en)	2013-06-21	2016-05-05	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
EA036400B1 (ru)	2013-06-28	2020-11-06	Этрис Гмбх	Композиции для введения рнк в клетки
JP6617702B2 (ja)	2013-07-15	2019-12-11	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｆｔｙ７２０のアザサイクリック拘束アナログ
TWI772856B (zh)	2013-07-19	2022-08-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
HRP20200250T1 (hr)	2013-08-08	2020-05-29	The Scripps Research Institute	Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
WO2015022326A1 (en)	2013-08-12	2015-02-19	Xiber Science Gmbh	Peptides as active agents for treating primary graft dysfunction
WO2015036599A1 (en)	2013-09-16	2015-03-19	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Mutant calreticulin for the diagnosis of myeloid malignancies
US9943604B2 (en)	2013-09-20	2018-04-17	Ionis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
TWI669393B (zh)	2013-10-02	2019-08-21	艾爾妮蘭製藥公司	抑制ｌｅｃｔ２基因表現之組合物及方法
LT3052628T (lt)	2013-10-04	2020-09-10	Alnylam Pharmaceuticals, Inc.	Kompozicijos ir būdai alas1 geno raiškai nuslopinti
EP3055426B1 (de)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
EP3967770B1 (de)	2013-10-21	2023-12-06	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
EP3066219B1 (de)	2013-11-08	2018-12-26	Ionis Pharmaceuticals, Inc.	Verfahren zur detektion von oligonukleotiden
EP3750997A1 (de)	2013-12-02	2020-12-16	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
EP3076918A4 (de)	2013-12-03	2017-06-07	Northwestern University	Liposomale partikel, verfahren zur herstellung davon und verwendungen davon
WO2015085183A2 (en)	2013-12-06	2015-06-11	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
AU2014362262B2 (en)	2013-12-12	2021-05-13	Alnylam Pharmaceuticals, Inc.	Complement component iRNA compositions and methods of use thereof
JP6599334B2 (ja)	2013-12-20	2019-10-30	ザジェネラルホスピタルコーポレイション	血中循環腫瘍細胞に関する方法およびアッセイ
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
EP3095460A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
CN113278617A (zh)	2014-01-16	2021-08-20	波涛生命科学有限公司	手性设计
WO2015120075A2 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
EP3105331B1 (de)	2014-02-11	2021-06-23	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3104873B1 (de)	2014-02-13	2019-09-04	Technische Universität München	Fgf-8 zur verwendung zur behandlung von erkrankungen oder störungen der energiehomöostase
CN106414749A (zh)	2014-02-26	2017-02-15	埃泽瑞斯公司	用于胃肠给予rna的组合物
EP3119789B1 (de)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
LT3119888T (lt)	2014-03-19	2021-10-11	Ionis Pharmaceuticals, Inc.	Kompozicijos, skirtos ataksino 2 raiškos moduliavimui
SI3126499T1 (sl)	2014-04-01	2020-09-30	Biogen Ma Inc.	Sestave za moduliranje izražanja SOD-1
US10513706B2 (en)	2014-04-09	2019-12-24	The Scripps Research Institute	Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
EP3131576B1 (de)	2014-04-17	2021-06-30	Medizinische Hochschule Hannover	Mittel und verfahren zur herstellung von neisseria meningitidis kapsel-polysacchariden mit geringer dispersität
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
US9926556B2 (en)	2014-04-28	2018-03-27	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
BR122020024446B8 (pt)	2014-05-01	2022-06-28	Ionis Pharmaceuticals Inc	Compostos para modulação da expressão do receptor do hormônio de crescimento
EP3845547A1 (de)	2014-05-01	2021-07-07	Ionis Pharmaceuticals, Inc.	Galnac3-modifizierte oligonukleotid-konjugat zur modulierung der angiopoietin-like-3-expression
MX380866B (es)	2014-05-01	2025-03-12	Ionis Pharmaceuticals Inc	Composiciones y métodos para modular la expresión del factor b del complemento.
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
CN112301031A (zh)	2014-05-22	2021-02-02	阿尔尼拉姆医药品有限公司	血管紧张素原(AGT)iRNA组合物及其使用方法
US10570169B2 (en)	2014-05-22	2020-02-25	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
EP3148564B1 (de)	2014-06-02	2020-01-08	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur immunmodulation
CA2953216C (en)	2014-06-04	2020-12-22	Exicure, Inc.	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10308940B2 (en)	2014-06-10	2019-06-04	Erasmus University Medical Center Rotterdam	Antisense oligonucleotides useful in treatment of Pompe disease
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
WO2016018665A1 (en)	2014-07-31	2016-02-04	Uab Research Foundation	Apoe mimetic peptides and higher potency to clear plasma cholesterol
US12264344B2 (en)	2014-08-19	2025-04-01	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
US9617541B2 (en)	2014-08-20	2017-04-11	Northwestern University	Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation
AU2015308721B2 (en)	2014-08-29	2021-04-01	Children's Medical Center Corporation	Methods and compositions for the treatment of cancer
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3185957B1 (de)	2014-08-29	2022-06-01	Alnylam Pharmaceuticals, Inc.	Patisiran zur behandlung von transthyretin-vermittelter amyloidose
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
US10436802B2 (en)	2014-09-12	2019-10-08	Biogen Ma Inc.	Methods for treating spinal muscular atrophy
US10556020B2 (en)	2014-09-26	2020-02-11	University Of Massachusetts	RNA-modulating agents
US10227621B2 (en)	2014-09-30	2019-03-12	Basf Se	Method for preparing an aqueous acrylamide solution having a low acrylic acid concentration
WO2016050819A1 (en)	2014-09-30	2016-04-07	Basf Se	Method for preparing an acrylamide solution having a low acrylic acid concentration
JP7055633B2 (ja)	2014-09-30	2022-04-18	ビーエーエスエフソシエタス・ヨーロピア	アクリル酸含有量がより少ないアミド化合物を産生する手段および方法
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3212794B1 (de)	2014-10-30	2021-04-07	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2016077540A1 (en)	2014-11-12	2016-05-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of comp
US10822369B2 (en)	2014-11-14	2020-11-03	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of proteins
AU2015350120B2 (en)	2014-11-17	2021-05-27	Alnylam Pharmaceuticals, Inc.	Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
EP3220895B1 (de)	2014-11-21	2022-08-31	Northwestern University	Sequenzspezifische zelluläre aufnahme von sphärischen nukleinsäurenanopartikelkonjugaten
AU2015360794B2 (en)	2014-12-08	2021-07-08	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
JP6997623B2 (ja)	2014-12-12	2022-02-04	エム．ウルフ、トッド	オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法
EP3034539A1 (de)	2014-12-19	2016-06-22	Ethris GmbH	Zusammensetzungen zur Einführung von Nukleinsäure in Zellen
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
EP3247988A4 (de)	2015-01-23	2018-12-19	Vanderbilt University	Robustes interferometer und verfahren zur verwendung davon
WO2016130600A2 (en)	2015-02-09	2016-08-18	Duke University	Compositions and methods for epigenome editing
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262173A2 (de)	2015-02-23	2018-01-03	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
EP3722297A1 (de)	2015-03-04	2020-10-14	Gilead Sciences, Inc.	Toll-like-rezeptor-modulator-verbindungen
BR112017020750A2 (pt)	2015-03-27	2018-06-26	Harvard College	células t modificadas e métodos de produção e utilização das mesmas
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
CA2981960C (en)	2015-04-08	2023-09-19	The University Of Chicago	Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
EP3310918B1 (de)	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
JP2018524588A (ja)	2015-06-26	2018-08-30	ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド	骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法
IL256634B2 (en)	2015-06-29	2025-08-01	Caris Science Inc	Therapeutic oligonucleotides
EP3313989B1 (de)	2015-06-29	2024-12-25	Ionis Pharmaceuticals, Inc.	Modifizierte crispr-rna und modifizierte single-crispr-rna und verwendungen davon
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
ES2917181T3 (es)	2015-07-10	2022-07-07	Ionis Pharmaceuticals Inc	Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)
MA43072A (fr)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
WO2017019918A1 (en)	2015-07-28	2017-02-02	Caris Science, Inc.	Targeted oligonucleotides
EP3332009A1 (de)	2015-08-04	2018-06-13	Yeda Research and Development Co., Ltd.	Verfahren zum screening auf riboswitches und attenuatoren
EA201890619A1 (ru)	2015-09-02	2018-09-28	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP7041616B2 (ja)	2015-09-14	2022-03-24	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	リポカチオン性デンドリマーおよびその使用
EP3353328A4 (de)	2015-09-24	2019-06-12	Ionis Pharmaceuticals, Inc.	Modulatoren der kras-expression
JP2018532402A (ja)	2015-09-24	2018-11-08	クリスパーセラピューティクスアーゲー	Ｒｎａプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
JP6853539B2 (ja)	2015-09-24	2021-03-31	ザリージェンツオブザユニバーシティオブカリフォルニアＴｈｅＲｅｇｅｎｔｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣａｌｉｆｏｒｎｉａ	合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
US10709812B2 (en)	2015-09-29	2020-07-14	The Regents Of The University Of Michigan	Biodegradable hydrogel for tissue expansion
WO2017066497A2 (en)	2015-10-13	2017-04-20	Duke University	Genome engineering with type i crispr systems in eukaryotic cells
CN108513546A (zh)	2015-10-28	2018-09-07	克里斯珀医疗股份公司	用于治疗杜氏肌营养不良症的材料和方法
ES2870141T3 (es)	2015-10-30	2021-10-26	Hoffmann La Roche	Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
ES2938883T3 (es)	2015-11-05	2023-04-17	Los Angeles Childrens Hospital	Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
CN113952353A (zh)	2015-11-06	2022-01-21	Ionis制药公司	调节载脂蛋白(a)表达
BR112018008971A2 (pt)	2015-11-06	2018-11-27	Crispr Therapeutics Ag	materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
PT4119569T (pt)	2015-11-06	2024-10-23	Ionis Pharmaceuticals Inc	Compostos antissentido conjugados para utilização em terapia
US11001622B2 (en)	2015-11-19	2021-05-11	The Brigham And Women's Hospital, Inc.	Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
AU2016362282B2 (en)	2015-11-30	2023-03-16	Duke University	Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
WO2017093804A2 (en)	2015-12-01	2017-06-08	Crispr Therapeutics Ag	Materials and methods for treatment of alpha-1 antitrypsin deficiency
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
ES3041380T3 (en)	2015-12-07	2025-11-11	Genzyme Corp	Methods and compositions for treating a serpinc1-associated disorder
WO2017099579A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
EP3394260B1 (de)	2015-12-23	2021-02-17	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyothrophischer lateraler sklerose und/oder frontotemporaler demenz
EP3397288A4 (de)	2015-12-31	2019-09-11	Ionis Pharmaceuticals, Inc.	Verfahren zur reduzierung der ataxin-2-expression
EP3400300A4 (de)	2016-01-05	2019-08-07	Ionis Pharmaceuticals, Inc.	Verfahren zur reduzierung der lrrk2-expression
EP3408649B1 (de)	2016-01-29	2023-06-14	Vanderbilt University	Interferometrie mit antwortfunktion in freier lösung
WO2017134529A1 (en)	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
EP3411396A1 (de)	2016-02-04	2018-12-12	Curis, Inc.	Smoothened-mutant und verfahren zur verwendung davon
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
DK3419665T3 (da)	2016-02-25	2025-01-13	Brigham & Womens Hospital Inc	Behandlingsfremgangsmåder til fibrose ved målretning af SMOC2
WO2017152182A1 (en)	2016-03-04	2017-09-08	Rhode Island Hospital	Targeting microrna for cancer treatment
WO2017156242A1 (en)	2016-03-09	2017-09-14	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting pmp22 expression
US10961271B2 (en)	2016-03-16	2021-03-30	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
US10577607B2 (en)	2016-03-16	2020-03-03	Ionis Pharmaceuticals, Inc.	Modulation of DYRK1B expression
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
WO2017161357A1 (en)	2016-03-18	2017-09-21	Caris Science, Inc.	Oligonucleotide probes and uses thereof
EP3225694A1 (de)	2016-03-29	2017-10-04	Basf Se	Verfahren zur herstellung von acrylamid durch definierte zugabe des biokatalysators
RU2751919C2 (ru)	2016-03-29	2021-07-20	Басф Се	Способ получения раствора полиакриламида с увеличенной вязкостью
EP3225693A1 (de)	2016-03-29	2017-10-04	Basf Se	Verfahren zur herstellung von wässrigen acrylamidlösungen
AU2017248637A1 (en)	2016-04-13	2018-09-27	Ionis Pharmaceuticals, Inc.	Methods for reducing C9ORF72 expression
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2017178193A1 (en)	2016-04-14	2017-10-19	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Method for the identification of random polynucleotide or polypeptide sequences with biological activity
MX2018012729A (es)	2016-04-18	2019-07-04	Crispr Therapeutics Ag	Materiales y metodos para el tratamiento de hemoglobinopatias.
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017186685A1 (en)	2016-04-26	2017-11-02	Basf Se	Method for preparing an aqueous polyacrylamide solution
EP3448898A1 (de)	2016-04-26	2019-03-06	Basf Se	Verfahren zur herstellung einer wässrigen polyacrylamidlösung
US20190144574A1 (en)	2016-04-26	2019-05-16	Basf Se	Method for preparing an aqueous polyacrylamide solution
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CA3021994A1 (en)	2016-05-06	2017-11-09	Brett P. Monia	Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
CN109414408B (zh)	2016-05-16	2022-03-29	得克萨斯州大学系统董事会	阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
EP3464597B1 (de)	2016-05-25	2022-08-03	Caris Science, Inc.	Selectionsverfahren von oligonukleotidsonden und verwendungen davon
WO2017214518A1 (en)	2016-06-10	2017-12-14	Alnylam Pharmaceuticals, Inc.	COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
US11708614B2 (en)	2016-06-15	2023-07-25	Streck Llc	Assays and methods for determining microbial resistance
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
MA45496A (fr)	2016-06-17	2019-04-24	Hoffmann La Roche	Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
ES2929047T3 (es)	2016-06-24	2022-11-24	Scripps Research Inst	Transportador de nucleósido trifosfato novedoso y usos del mismo
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
AU2017290614C1 (en)	2016-06-29	2024-01-18	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP3481857A1 (de)	2016-07-06	2019-05-15	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schmerbedingten erkrankungen
AU2017292169B2 (en)	2016-07-06	2021-12-23	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
AU2017296195A1 (en)	2016-07-11	2019-01-24	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
PE20190513A1 (es)	2016-07-15	2019-04-10	Ionis Pharmaceuticals Inc	Compuestos y metodos para la modulacion de smn2
EP4275747A3 (de)	2016-07-19	2024-01-24	Duke University	Therapeutische anwendungen von cpf1-basierter genomeditierung
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018035380A1 (en)	2016-08-17	2018-02-22	Solstice Biologics, Ltd.	Polynucleotide constructs
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
SG10201607303YA (en)	2016-09-01	2018-04-27	Agency Science Tech & Res	Antisense oligonucleotides to induce exon skipping
US10640499B2 (en)	2016-09-02	2020-05-05	Gilead Sciences, Inc.	Toll like receptor modulator compounds
ES2906581T3 (es)	2016-09-02	2022-04-19	Gilead Sciences Inc	Compuestos moduladores de los receptores tipo Toll
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
JOP20190065A1 (ar)	2016-09-29	2019-03-28	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن tau
CN109661233A (zh)	2016-10-06	2019-04-19	Ionis 制药公司	缀合低聚化合物的方法
SG10201609048RA (en)	2016-10-28	2018-05-30	Agency Science Tech & Res	Antisense oligonucleotides
US11459568B2 (en)	2016-10-31	2022-10-04	University Of Massachusetts	Targeting microRNA-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
TWI788312B (zh)	2016-11-23	2023-01-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
JP7206214B2 (ja)	2016-12-13	2023-01-17	シアトルチルドレンズホスピタル（ディービーエイシアトルチルドレンズリサーチインスティテュート）	インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
TWI790217B (zh)	2016-12-16	2023-01-21	美商阿尼拉製藥公司	使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
RU2019126483A (ru)	2017-01-23	2021-02-24	Ридженерон Фармасьютикалз, Инк.	Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US11559588B2 (en)	2017-02-22	2023-01-24	Crispr Therapeutics Ag	Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
JP2020508056A (ja)	2017-02-22	2020-03-19	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	遺伝子編集のための組成物および方法
US11407997B2 (en)	2017-02-22	2022-08-09	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
WO2018165564A1 (en)	2017-03-09	2018-09-13	Ionis Pharmaceuticals, Inc.	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
US20180284123A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
WO2018185222A1 (en)	2017-04-05	2018-10-11	Acib Gmbh - Austrian Centre Of Industrial Biotechnology	Aminoacyl trna synthetases and orthogonal trnas
IL269970B (en)	2017-04-14	2022-09-01	Tallac Therapeutics Inc	Polynucleotides that modulate the immune system, their antibody binding, and methods of using them
CN118384268A (zh)	2017-04-18	2024-07-26	阿尔尼拉姆医药品有限公司	具有乙肝病毒（hbv）感染的受试者的治疗方法
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
KR102778110B1 (ko)	2017-04-20	2025-03-10	신테나 아게	트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
JP7356354B2 (ja)	2017-05-12	2023-10-04	クリスパーセラピューティクスアクチェンゲゼルシャフト	細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
JP2020530442A (ja)	2017-07-10	2020-10-22	ジェンザイム・コーポレーション	血友病を有する対象の出血事象を処置するための方法および組成物
CN111051512A (zh)	2017-07-11	2020-04-21	辛索克斯公司	非天然核苷酸的掺入及其方法
KR20200028997A (ko)	2017-07-13	2020-03-17	노오쓰웨스턴 유니버시티	올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
AU2018301477A1 (en)	2017-07-13	2020-02-27	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
EP3658176A1 (de)	2017-07-26	2020-06-03	Medizinische Universität Wien	Superaktive mutante thymidinkinase zur verwendung in der krebstherapie
SG11202000939PA (en)	2017-08-03	2020-02-27	Synthorx Inc	Cytokine conjugates for the treatment of proliferative and infectious diseases
CA3071033A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
WO2019055460A1 (en)	2017-09-13	2019-03-21	The Children's Medical Center Corporation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
KR20250046363A (ko)	2017-09-19	2025-04-02	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
PE20200868A1 (es)	2017-10-16	2020-08-31	Hoffmann La Roche	OLIGONUCLEOTIDOS ANTISENTIDO Y CONJUGADOS QUE LOS COMPRENDEN PARA LA REDUCCION DEL ARNm DE PAPD5 Y PAPD7
MA50833A (fr)	2017-10-17	2020-08-26	Bayer Healthcare Llc	Compositions et méthodes pour l'édition génique pour l'hémophilie a
WO2019081982A1 (en)	2017-10-26	2019-05-02	Crispr Therapeutics Ag	SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
SG11202002940QA (en)	2017-11-01	2020-04-29	Alnylam Pharmaceuticals Inc	Complement component c3 irna compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
EP3707155A2 (de)	2017-11-09	2020-09-16	Vertex Pharmaceuticals Incorporated	Crispr/cas-systeme für die behandlung von dmd
EP3710587A1 (de)	2017-11-16	2020-09-23	Alnylam Pharmaceuticals, Inc.	Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
US10662425B2 (en)	2017-11-21	2020-05-26	Crispr Therapeutics Ag	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
MA51107A (fr)	2017-12-05	2020-10-14	Vertex Pharma	Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées
US11725208B2 (en)	2017-12-14	2023-08-15	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
CN111801417B (zh)	2017-12-14	2024-10-29	克里斯珀医疗股份公司	新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途
CN111727252A (zh)	2017-12-18	2020-09-29	阿尔尼拉姆医药品有限公司	高速泳动族盒-1（HMGB1）iRNA组合物及其使用方法
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
EP3728595A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
JP7402163B2 (ja)	2017-12-21	2023-12-20	クリスパーセラピューティクスアーゲー	２ａ型アッシャー症候群の処置のための材料および方法
IL319501A (en)	2017-12-29	2025-05-01	Scripps Research Inst	Unnatural nucleotide compounds and methods of using them
US12178855B2 (en)	2018-01-10	2024-12-31	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
CA3088180A1 (en)	2018-01-12	2019-07-18	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting transferrin
SG11202006528XA (en)	2018-01-12	2020-08-28	Bristol Myers Squibb Co	Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh)	2018-01-12	2025-07-15	百时美施贵宝公司	靶向α-突触核蛋白的反义寡核苷酸及其用途
JP2021511072A (ja)	2018-01-15	2021-05-06	アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｄｎｍ２発現のモジュレーター
US12319667B2 (en)	2018-01-19	2025-06-03	Synthena Ag	Tricyclo-DNA nucleoside precursors and processes for preparing the same
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
WO2019150203A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
EP3749767A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
AU2019218987B2 (en)	2018-02-12	2025-04-24	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
WO2019161310A1 (en)	2018-02-16	2019-08-22	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting fibrinogen-alpha
AR114445A1 (es)	2018-02-26	2020-09-09	Synthorx Inc	Conjugados de il-15, y sus usos
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
EP3768834B1 (de)	2018-03-19	2025-08-13	CRISPR Therapeutics AG	Neuartige rna-programmierbare endonukleasesysteme und deren verwendung in der genombearbeitung und in anderen anwendungen
US11661601B2 (en)	2018-03-22	2023-05-30	Ionis Pharmaceuticals, Inc.	Methods for modulating FMR1 expression
CN112513297B (zh)	2018-03-28	2024-10-22	得克萨斯州大学系统董事会	鉴定从外排体分离的dna中的表观遗传改变
WO2019186514A2 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
WO2019195738A1 (en)	2018-04-06	2019-10-10	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
CA3094020A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
ES2960939T3 (es)	2018-04-25	2024-03-07	Ethris Gmbh	Agentes crioprotectores para formulaciones particuladas
CA3091490A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
WO2019213016A1 (en)	2018-04-30	2019-11-07	The Children's Hospital Of Philadelphia	Methods of improving anemias by combining agents
WO2019213571A1 (en)	2018-05-03	2019-11-07	The Trustees Of Wheaton College	Improved membranes for nanopore sensing applications
MX2020011911A (es)	2018-05-09	2021-01-29	Ionis Pharmaceuticals Inc	Compuestos y metodos para reducir de la expresion de atxn3.
MY204000A (en)	2018-05-09	2024-07-31	Ionis Pharmaceuticals Inc	Compounds and methods for reducing fxi expression
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
WO2019238725A1 (en)	2018-06-13	2019-12-19	Acib Gmbh - Austrian Centre Of Industrial Biotechnology	Methionine analogue synthesis
JP7557378B2 (ja)	2018-06-14	2024-09-27	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｓｔｍｎ２発現を増加させるための化合物及び方法
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
KR102585973B1 (ko)	2018-07-03	2023-10-10	에프. 호프만-라 로슈 아게	타우 발현을 조절하기 위한 올리고뉴클레오티드
EP3823725A4 (de)	2018-07-17	2023-05-10	Aronora, Inc.	Verfahren zur sicheren reduzierung von thrombopoietin
TWI843738B (zh)	2018-07-25	2024-06-01	美商Ionis製藥公司	用於減少atxn2表現之化合物及方法
BR112021001613A2 (pt)	2018-08-13	2021-05-04	Alnylam Pharmaceuticals, Inc.	agentes de ácido ribonucleico de fita dupla, célula, composições farmacêuticas, métodos de inibição da expressão gênica, de inibição da replicação e de tratar um sujeito, métodos para reduzir o nível de um antígeno e para reduzir a carga viral e uso de um agente de dsrna
EP3837367A1 (de)	2018-08-16	2021-06-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
EA202190581A1 (ru)	2018-08-20	2021-07-13	Рогкон, Инк.	Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
WO2020047229A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
EP3844270B1 (de)	2018-08-31	2023-07-12	Leibniz-Institut für Pflanzenbiochemie (IPB)	Kalzium-abhängige protein kinase-konstrukte und deren verwendung
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
US20210254067A1 (en)	2018-09-11	2021-08-19	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheilt und Umwelt (GmbH)	Microrna inhibitors for use in treating metabolic diseases
AU2019339509A1 (en)	2018-09-14	2021-05-13	Northwestern University	Programming protein polymerization with DNA
EP3853364A1 (de)	2018-09-18	2021-07-28	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
TWI869213B (zh)	2018-09-19	2025-01-01	美商Ionis製藥公司	Pnpla3表現之調節劑
CA3292164A1 (en)	2018-09-25	2025-11-29	Co Diagnostics Inc	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
WO2020070325A1 (en)	2018-10-05	2020-04-09	Multiplex Dx	Method for diagnosing diseases using multiplex fluorescence and sequencing
BR112021007403A2 (pt)	2018-10-17	2021-12-07	Bayer Healthcare Llc	Composições e métodos para entrega de transgenes
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
AU2019376076B9 (en)	2018-11-08	2025-06-19	Synthorx, Inc.	Interleukin 10 conjugates and uses thereof
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
SG11202104666SA (en)	2018-11-15	2021-06-29	Ionis Pharmaceuticals Inc	Modulators of irf5 expression
BR112021007476A2 (pt)	2018-11-21	2021-11-03	Ionis Pharmaceuticals Inc	Compostos e métodos para reduzir a expressão de príon
CN113710799B (zh)	2018-11-28	2024-11-12	克里斯珀医疗股份公司	用于在LNP中使用的编码CAS9的优化mRNA
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
US20210332495A1 (en)	2018-12-06	2021-10-28	Northwestern University	Protein Crystal Engineering Through DNA Hybridization Interactions
MA54452A (fr)	2018-12-10	2022-03-16	Ideaya Biosciences Inc	Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
HRP20231338T1 (hr)	2018-12-20	2024-02-16	Vir Biotechnology, Inc.	Kombinirana terapija hbv
AU2019406186A1 (en)	2018-12-20	2021-07-15	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of KCNT1 related disorders
AU2019406214A1 (en)	2018-12-21	2021-08-05	Northwestern University	Use of annexins in preventing and treating muscle membrane injury
MX2021007503A (es)	2018-12-21	2021-08-05	Ionis Pharmaceuticals Inc	Moduladores de la expresion de hsd17b13.
WO2020139977A1 (en)	2018-12-26	2020-07-02	Northwestern University	Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
CN113557023A (zh)	2019-01-16	2021-10-26	建新公司	Serpinc1 iRNA组合物及其使用方法
WO2020160453A1 (en)	2019-01-31	2020-08-06	Ionis Pharmaceuticals, Inc.	Modulators of yap1 expression
AU2020218203A1 (en)	2019-02-06	2021-08-26	Synthorx, Inc.	IL-2 conjugates and methods of use thereof
AU2020221340A1 (en)	2019-02-15	2021-09-16	Bayer Healthcare Llc	Gene editing for hemophilia A with improved Factor VIII expression
MY208565A (en)	2019-02-27	2025-05-15	Ionis Pharmaceuticals Inc	Modulators of malat1 expression
US20220175956A1 (en)	2019-03-06	2022-06-09	Northwestern University	Hairpin-like oligonucleotide-conjugated spherical nucleic acid
CN113924127A (zh)	2019-03-11	2022-01-11	奥克斯纳健康系统公司	在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络
WO2020186059A2 (en)	2019-03-12	2020-09-17	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
CR20210538A (es)	2019-03-29	2021-12-06	Ionis Pharmaceuticals Inc	Compuestos y métodos para modular ube3a-ats
TWI751517B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TWI751516B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
PH12021552870A1 (en)	2019-05-13	2022-03-21	Vir Biotechnology Inc	Compositions and methods for treating hepatitis b virus (hbv) infection
ES3033104T3 (en)	2019-05-28	2025-07-30	Ionis Pharmaceuticals Inc	Compounds and methods for reducing fus expression
US20250270657A1 (en)	2019-05-31	2025-08-28	Streck, Inc.	Detection of Antibiotic Resistance Genes
EP3983543A4 (de)	2019-06-14	2023-05-03	The Scripps Research Institute	Reagenzien und verfahren zur replikation, transkription und translation in halbsynthetischen organismen
TWI879779B (zh)	2019-06-28	2025-04-11	美商基利科學股份有限公司	類鐸受體調節劑化合物的製備方法
ES3048358T3 (en)	2019-07-26	2025-12-10	Ionis Pharmaceuticals Inc	Compounds and methods for modulating gfap
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4031658A1 (de)	2019-08-07	2022-07-27	DB Biotech, AS	Verbesserte meerrettichperoxidase-polypeptide
EP4013870A1 (de)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
JP7679355B2 (ja)	2019-08-15	2025-05-19	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートを用いる免疫腫瘍学併用療
WO2021041206A1 (en)	2019-08-23	2021-03-04	Synthorx, Inc.	Il-15 conjugates and uses thereof
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
US20220332799A1 (en)	2019-09-04	2022-10-20	Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne)	Herv inhibitors for use in treating tauopathies
TW202124385A (zh)	2019-09-10	2021-07-01	美商欣爍克斯公司	治療自體免疫疾病之il-2接合物及使用方法
WO2021048257A1 (en)	2019-09-11	2021-03-18	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Bactericidal phage vectors
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
EP4038189A1 (de)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
JP7757277B2 (ja)	2019-10-14	2025-10-21	アストラゼネカ・アクチエボラーグ	Ｐｎｐｌａ３発現のモジュレーター
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
EP4048793A1 (de)	2019-10-22	2022-08-31	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
US20240168004A1 (en)	2019-10-31	2024-05-23	The Trustees Of Wheaton College	Design and characterization of multilayered structures for support of lipid bilayers
CA3155921A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
CA3156405A1 (en)	2019-11-04	2021-05-14	Synthorx, Inc.	Interleukin 10 conjugates and uses thereof
MX2022005430A (es)	2019-11-05	2022-05-26	Basf Se	Metodo de almacenamiento de un biocatalizador.
CN114981431A (zh)	2019-11-13	2022-08-30	阿尔尼拉姆医药品有限公司	用于治疗血管紧张素原(agt)相关病症的方法和组合物
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
CN115335521A (zh)	2019-11-27	2022-11-11	克里斯珀医疗股份公司	合成rna分子的方法
BR112022011417A2 (pt)	2019-12-13	2022-08-30	Alnylam Pharmaceuticals Inc	Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
US20230054569A1 (en)	2019-12-18	2023-02-23	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
WO2021142245A1 (en)	2020-01-10	2021-07-15	Translate Bio, Inc.	Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
WO2021154705A1 (en)	2020-01-27	2021-08-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
EP4100423A1 (de)	2020-02-03	2022-12-14	Medizinische Universität Wien	Modifizierte filamine und deren verwendungen
CA3170377A1 (en)	2020-02-10	2021-08-19	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing vegf-a expression
JP7735288B2 (ja)	2020-02-18	2025-09-08	アルナイラムファーマシューティカルズ，インコーポレイテッド	アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
JP7446443B2 (ja)	2020-02-28	2024-03-08	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｓｍｎ２を調節するための化合物及び方法
US11920136B2 (en)	2020-02-28	2024-03-05	Tallac Therapeutics, Inc.	Transglutaminase-mediated conjugation
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
EP4114948A1 (de)	2020-03-06	2023-01-11	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021186035A1 (en)	2020-03-20	2021-09-23	Medizinische Universität Wien	Cyclotides in combination with kappa opioid receptor ligands for ms therapy
JP2023519274A (ja)	2020-03-26	2023-05-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	コロナウイルスｉＲＮＡ組成物およびその使用方法
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
US20230295622A1 (en)	2020-04-06	2023-09-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
US20230159933A1 (en)	2020-04-07	2023-05-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN111995649A (zh) *	2020-04-09	2020-11-27	瀚海新拓(杭州)生物医药有限公司	一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途
BR112022021462A2 (pt)	2020-04-21	2023-01-17	Flagship Pioneering Inc	Moléculas bifuncionais e métodos de sua utilização
EP4143319A1 (de)	2020-04-27	2023-03-08	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
CN116096381A (zh)	2020-04-30	2023-05-09	阿尔尼拉姆医药品有限公司	补体因子B（CFB）iRNA组合物及其使用方法
IL297435A (en)	2020-05-01	2022-12-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating atxn1
CA3177559A1 (en)	2020-05-04	2021-11-11	Pavol Cekan	Means and methods for detecting novel coronavirus (sars-cov-2)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150086A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
US20230183707A1 (en)	2020-05-21	2023-06-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
CN116075592A (zh)	2020-06-09	2023-05-05	阿尔尼拉姆医药品有限公司	用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
WO2021257782A1 (en)	2020-06-18	2021-12-23	Alnylam Pharmaceuticals, Inc.	XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL299201A (en)	2020-06-24	2023-02-01	Vir Biotechnology Inc	Transgenic hepatitis B virus neutralizing antibodies and their uses
KR20230027235A (ko)	2020-06-25	2023-02-27	신톡스, 인크.	Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
JP2023532518A (ja)	2020-06-29	2023-07-28	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｐｌｐ１を調節するための化合物及び方法
WO2022003142A1 (en)	2020-07-03	2022-01-06	Engenes Biotech Gmbh	PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF
BR112023001624A2 (pt)	2020-07-28	2023-02-23	Ionis Pharmaceuticals Inc	Compostos e métodos para reduzir a expressão de app
JP2023536994A (ja)	2020-08-07	2023-08-30	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｓｃｎ２ａを調節する化合物および方法
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3193353A1 (en)	2020-09-24	2022-03-31	Carina WEHNER	Prame specific t-cell receptors and uses thereof
US20230392134A1 (en)	2020-09-30	2023-12-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
WO2022076291A1 (en)	2020-10-05	2022-04-14	Alnylam Pharmaceuticals, Inc.	G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
CA3194880A1 (en)	2020-10-09	2022-04-14	Carolina E. CAFFARO	Immuno oncology therapies with il-2 conjugates
CN116615235A (zh)	2020-10-09	2023-08-18	得克萨斯州大学系统董事会	融合前稳定的hmpv f蛋白
JP2023546009A (ja)	2020-10-09	2023-11-01	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよびペムブロリズマブを用いる免疫腫瘍学併用療法
EP4232581A1 (de)	2020-10-21	2023-08-30	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
CN116761885A (zh)	2020-10-23	2023-09-15	斯克利普斯研究所	包含非天然核苷酸的多核苷酸的逆转录
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4244355A1 (de)	2020-11-13	2023-09-20	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor-v (f5)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230108728A (ko)	2020-11-18	2023-07-18	아이오니스 파마수티컬즈, 인코포레이티드	앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
WO2022106695A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
US11987795B2 (en)	2020-11-24	2024-05-21	The Broad Institute, Inc.	Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
CA3201452A1 (en)	2020-12-01	2022-06-09	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (de)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
CA3205040A1 (en)	2020-12-18	2022-06-23	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor xii
US20240175020A1 (en)	2020-12-23	2024-05-30	Flagship Pioneering Innovations Vi, Llc	Compositions of modified trems and uses thereof
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2022174000A2 (en)	2021-02-12	2022-08-18	Alnylam Pharmaceuticals, Inc.	Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
EP4291243A1 (de)	2021-02-12	2023-12-20	Synthorx, Inc.	Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
CN117222739A (zh)	2021-02-25	2023-12-12	阿尔尼拉姆医药品有限公司	朊病毒蛋白(prnp)irna组合物和其使用方法
AU2022226098A1 (en)	2021-02-26	2023-08-24	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508896A (ja)	2021-03-04	2024-02-28	アルナイラムファーマシューティカルズ，インコーポレイテッド	アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
US20220288181A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
TW202305134A (zh)	2021-03-29	2023-02-01	美商艾拉倫製藥股份有限公司	杭丁頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022214632A1 (en)	2021-04-07	2022-10-13	Neoplants Sas	Compositions and methods for indoor air remediation
AU2022262422A1 (en)	2021-04-22	2023-11-02	The Board Of Regents Of The University Of Texas System	All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
IL307926A (en)	2021-04-26	2023-12-01	Alnylam Pharmaceuticals Inc	Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
JP2024522068A (ja)	2021-05-18	2024-06-11	アルナイラムファーマシューティカルズ，インコーポレイテッド	ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
WO2022256395A1 (en)	2021-06-02	2022-12-08	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
TW202308663A (zh)	2021-06-04	2023-03-01	美商艾拉倫製藥股份有限公司	人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法
AR126070A1 (es)	2021-06-08	2023-09-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
BR112023023768A2 (pt)	2021-06-11	2024-02-27	Bayer Ag	Sistemas de endonucleases programáveis por rna tipo v
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
MX2023015230A (es)	2021-06-18	2024-01-18	Ionis Pharmaceuticals Inc	Compuestos y metodos para reducir la expresion de ifnar1.
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
MX2023015489A (es)	2021-06-30	2024-01-19	Alnylam Pharmaceuticals Inc	Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt).
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
EP4119581A1 (de)	2021-07-14	2023-01-18	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH	Neuartige fab-dimere
TW202325312A (zh)	2021-07-23	2023-07-01	美商艾拉倫製藥股份有限公司	β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法
EP4377458A1 (de)	2021-07-29	2024-06-05	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3227852A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
IL310295A (en)	2021-08-04	2024-03-01	Alnylam Pharmaceuticals Inc	iRNA compositions and methods for silencing angiotensinogen (AGT)
JP2024534766A (ja)	2021-08-13	2024-09-26	アルナイラムファーマシューティカルズ，インコーポレイテッド	第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
EP4395790A2 (de)	2021-08-31	2024-07-10	Alnylam Pharmaceuticals, Inc.	Zelltodinduzierende dffa-ähnliche effektor-b (cideb)-irna-zusammensetzungen und verfahren zur verwendung davon
US11833221B2 (en)	2021-09-01	2023-12-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds for reducing DMPK expression
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
EP4401742A2 (de)	2021-09-17	2024-07-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen und verfahren zur dämpfung der komplementkomponente 3 (c3)
CN118159654A (zh)	2021-09-20	2024-06-07	阿尔尼拉姆医药品有限公司	抑制素亚基βE（INHBE）调节剂组合物及其使用方法
PE20241065A1 (es)	2021-09-30	2024-05-13	Akouos Inc	Composiciones y metodos para el tratamiento de la perdida de audicion asociada a kcnq4
CA3233755A1 (en)	2021-10-01	2023-04-06	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
WO2023069603A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
EP4423272A2 (de)	2021-10-29	2024-09-04	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
US20250019702A1 (en)	2021-11-10	2025-01-16	University Of Rochester	Gata4-targeted therapeutics for treatment of cardiac hypertrophy
EP4430187A2 (de)	2021-11-10	2024-09-18	University of Rochester	Antisense oligonukleotide zur änderung der proteinexpression
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
CA3243006A1 (en)	2021-12-21	2025-02-27	Alia Therapeutics Srl	TYPE II CAS PROTEINS AND THEIR APPLICATIONS
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4453191A1 (de)	2021-12-23	2024-10-30	Bayer Aktiengesellschaft	Neuartige programmierbare endonukleasesysteme für kleine v-rna
EP4215042A1 (de)	2022-01-21	2023-07-26	Max-Delbrück-Centrum für Molekulare Medizin	Nicht-menschliches säugetier mit mindestens zwei menschlichen leukozytenantigenen (hla) der klasse i allele in seinem genom, verfahren zur herstellung eines solchen säugetiers und dessen verwendungen
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
EP4486890A1 (de)	2022-03-01	2025-01-08	CRISPR Therapeutics AG	Verfahren und zusammensetzungen zur behandlung von angiopoietin-like 3 (angptl3)-bedingten erkrankungen
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
IL316824A (en)	2022-06-10	2025-01-01	Bayer Ag	Novel small, programmable endonuclease systems for type V RNA
EP4299753A1 (de)	2022-06-29	2024-01-03	enGenes Biotech GmbH	Verfahren zum produzieren extrachromosomaler nukleinsäuren
CN119317722A (zh)	2022-06-29	2025-01-14	武田药品工业株式会社	用于生产染色体外核酸的方法
CN120077130A (zh)	2022-08-18	2025-05-30	阿尔尼拉姆医药品有限公司	通用非靶向sirna组合物及其使用方法
EP4581143A1 (de)	2022-08-29	2025-07-09	University of Rochester	Anti-fibrotische therapeutika auf der basis von antisense-oligonukleotiden
CN119923403A (zh)	2022-08-31	2025-05-02	帝斯曼知识产权资产管理有限公司	青春双歧杆菌菌株、其用于降解淀粉和调节非人类哺乳动物中的肠道菌群的方法和用途
MA71735A (fr)	2022-09-15	2025-05-30	Regeneron Pharmaceuticals, Inc.	Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
EP4587564A2 (de)	2022-09-16	2025-07-23	Alia Therapeutics Srl	Enqp-typ-ii-cas-proteine und anwendungen davon
AU2023347222A1 (en)	2022-09-23	2025-03-27	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing mecp2 expression
EP4609196A1 (de)	2022-10-26	2025-09-03	Eximmium Biotechnologies GmbH	Verfahren zur bestimmung der extrazellulären vesikelrückgewinnung
EP4619535A1 (de)	2022-11-16	2025-09-24	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
WO2024115430A1 (en)	2022-11-28	2024-06-06	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Acinetobacter baumannii phages
AU2023398007A1 (en)	2022-12-13	2025-06-19	Bayer Aktiengesellschaft	Engineered type v rna programmable endonucleases and their uses
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
IL321992A (en)	2023-01-09	2025-09-01	Univ Texas	Human parainfluenza virus 3f proteins stabilized before transfusion
EP4649147A2 (de)	2023-01-11	2025-11-19	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
WO2024168010A2 (en)	2023-02-09	2024-08-15	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof
EP4665865A1 (de)	2023-02-17	2025-12-24	Anjarium Biosciences AG	Verfahren zur herstellung von dna-molekülen und zusammensetzungen und verwendungen davon
WO2024180222A1 (en)	2023-03-02	2024-09-06	Universitaet Des Saarlandes	Methods for producing l-pipecolic acid
TW202444349A (zh)	2023-03-20	2024-11-16	美商欣爍克斯公司	使用ｉｌ－２綴合物之癌症療法
US12383615B2 (en)	2023-03-23	2025-08-12	Carbon Biosciences, Inc.	Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
WO2024196965A1 (en)	2023-03-23	2024-09-26	Carbon Biosciences, Inc.	Parvovirus compositions and related methods for gene therapy
AU2024244071A1 (en)	2023-04-06	2025-10-30	Shanghai Argo Biopharmaceutical Co., Ltd.	Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
TW202448484A (zh)	2023-04-20	2024-12-16	美商雅迪克斯製藥公司	Ｍａｐｔ調節組合物及其使用方法
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
TW202502385A (zh)	2023-05-12	2025-01-16	美商雅迪克斯製藥公司	Ｎｍｄａ配位體結合之化合物及其用途
WO2024243062A1 (en)	2023-05-19	2024-11-28	Streck Llc	Detection of antibiotic resistance genes
AU2024279767A1 (en)	2023-05-26	2025-12-04	Adarx Pharmaceuticals, Inc.	Sod1-modulating compositions and methods of use thereof
WO2024263694A1 (en)	2023-06-20	2024-12-26	Adarx Pharmaceuticals, Inc.	Lrrk2-modulating compositions and methods of use thereof
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2025015335A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025024486A2 (en)	2023-07-25	2025-01-30	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
WO2025024493A1 (en)	2023-07-25	2025-01-30	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
WO2025034422A1 (en)	2023-08-04	2025-02-13	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating ctnnb1-associated disorders
GB202314724D0 (en)	2023-09-26	2023-11-08	Astrazeneca Ab	compounds and methods for reducing psd3 expression
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
TW202521691A (zh)	2023-10-06	2025-06-01	美商藍岩醫療公司	經工程化之v型rna可程式核酸內切酶及其用途
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104216A1 (en)	2023-11-15	2025-05-22	Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)	Bacteriophage compositions
WO2025114609A1 (en)	2023-12-01	2025-06-05	MultiplexDX, s.r.o.	Method for predicting the efficacy of an antibody-drug-conjugate (adc) using multiplex fluorescence in situ hybridization (fish) and multiplex sequencing
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025165891A1 (en)	2024-01-29	2025-08-07	Arnatar Therapeutics, Inc	Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
US20250263702A1 (en)	2024-02-19	2025-08-21	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en)	2024-03-26	2024-05-08	Senisca Ltd	Novel oligoncleotides
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025242868A1 (en)	2024-05-23	2025-11-27	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Phage composition
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2081410B1 (de) *	1970-01-06	1974-08-23	Ciba Geigy Ag
US3792036A (en) *	1970-01-07	1974-02-12	Ciba Geigy Corp	Pteridine-glycosides
FR2081415A1 (en) *	1970-01-07	1971-12-03	Ciba Geigy Ag	Tetrahydropteridine-glycosides as anti- - virals and antimacarials
GB2056459B (en) *	1979-07-04	1983-03-09	Daiichi Radioisotope Lab	Pterin derivatives and an assay method for determining pterins
JPH0725788B2 (ja) *	1985-09-09	1995-03-22	帝人株式会社	オリゴまたはポリヌクレオチド
US5270465A (en) *	1989-03-30	1993-12-14	Lipha, Lyonnaise Industrille Pharmaceutique	4(3H)-pteridinone compounds
US5034393A (en) *	1989-07-27	1991-07-23	Dowelanco	Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
CA2033692A1 (en) *	1990-01-25	1991-07-26	Wilhelm Bannwarth	Energy transfer systems
ATE244259T1 (de) *	1992-02-12	2003-07-15	Chromagen Inc	Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen

1994
- 1994-05-18 US US08/245,923 patent/US5525711A/en not_active Expired - Lifetime
1995
- 1995-04-25 AU AU23991/95A patent/AU688036B2/en not_active Ceased
- 1995-04-25 DK DK95917197T patent/DK0759927T3/da active
- 1995-04-25 CA CA002190588A patent/CA2190588C/en not_active Expired - Fee Related
- 1995-04-25 WO PCT/US1995/005264 patent/WO1995031469A1/en not_active Ceased
- 1995-04-25 JP JP7529675A patent/JPH10500949A/ja not_active Withdrawn
- 1995-04-25 AT AT95917197T patent/ATE167680T1/de not_active IP Right Cessation
- 1995-04-25 ES ES95917197T patent/ES2118593T3/es not_active Expired - Lifetime
- 1995-04-25 EP EP95917197A patent/EP0759927B1/de not_active Expired - Lifetime
- 1995-04-25 DE DE69503129T patent/DE69503129T2/de not_active Expired - Fee Related
- 1995-05-26 US US08/451,641 patent/US5612468A/en not_active Expired - Lifetime
2008
- 2008-10-08 JP JP2008261724A patent/JP2009091358A/ja active Pending

Also Published As

Publication number	Publication date
US5525711A (en)	1996-06-11
CA2190588C (en)	2003-03-18
JP2009091358A (ja)	2009-04-30
AU688036B2 (en)	1998-03-05
EP0759927A1 (de)	1997-03-05
DK0759927T3 (da)	1999-04-06
ES2118593T3 (es)	1998-09-16
WO1995031469A1 (en)	1995-11-23
DE69503129T2 (de)	1999-02-18
EP0759927B1 (de)	1998-06-24
US5612468A (en)	1997-03-18
JPH10500949A (ja)	1998-01-27
CA2190588A1 (en)	1995-11-23
AU2399195A (en)	1995-12-05
DE69503129D1 (de)	1998-07-30

Publication	Publication Date	Title
DE69503129D1 (de)	1998-07-30	Pteridin-nukleotidderivate als fluoreszierende sonden
DE69333073D1 (de)	2003-08-07	Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
ATE454468T1 (de)	2010-01-15	Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
DE69638183D1 (de)	2010-06-17	Verwendung von nukleinsäureliganden in der durchflusszytometrie
NO20000536L (no)	2000-08-04	Oligonucleotide primere for effektiv detektering av Hepatitt C-virus (HCV) og metoder for anvendelse derav
NO940744L (de)	1994-05-02
ATE380883T1 (de)	2007-12-15	Direkte multiplex charakterisierung von genomischer dna
DE69637156D1 (de)	2007-08-23	Dna-molekül, herstellung und verwendung in der gentherapie
BRPI0410634A (pt)	2006-06-13	processo
BR0109062A (pt)	2002-11-26	Inibidores de frutose-1,6-bisfosfatase de arila
WO2001047944A3 (en)	2003-02-20	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002022879A3 (en)	2003-08-21	Detection of microsatellite instability and its use in diagnosis of tumors
AU3054502A (en)	2002-05-06	Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
DE59712871D1 (de)	2007-09-20	Heterocyclische verbindungen und deren verwendung in der detektion von nucleinsäuren
WO2000029623A3 (en)	2001-04-19	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69815370D1 (de)	2003-07-10	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
DE60029225D1 (de)	2006-08-17	Zusammensetzungen und verfahren zu höhere empfindlichkeit und spezifität von nukleinsäuresynthese
ATE207544T1 (de)	2001-11-15	Amplikationsprimern und nukleinsäuresonden zum nachweis von coccidioides immites
DE69943134D1 (de)	2011-02-24	Nukleinsäureamplifizierung und detektion von mykobacterium-spezies
ATE415491T1 (de)	2008-12-15	Oligonucleotide zur markierung von oligonukleotidsonden und proteine
ATE364616T1 (de)	2007-07-15	Nucleinsäuremolekül, kit und verwendung
WO2001040521A3 (en)	2002-05-16	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69928543D1 (de)	2005-12-29	Pteridine-nukleotid-analoge
DE69726276D1 (de)	2003-12-24	In situ herstellung von nukleosid-phosphoramiditen und ihre verwendung in der oligonukleotidsynthese
WO2000029622A3 (en)	2002-04-25	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date	Code	Title	Description
2011-01-15	REN	Ceased due to non-payment of the annual fee